Cytek Biosciences, Inc. (CTKB) 10-Year Financial Performance & Capital Metrics

CTKB • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentMedical Imaging Systems

AboutCytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.Show more

Revenue $200M +3.9%
EBITDA -$10M +46.1%
Net Income -$6M +50.4%
EPS (Diluted) -0.05 +48.7%
Gross Margin 55.43% -2.2%
EBITDA Margin -5.01% +48.1%
Operating Margin -10.24% +29.0%
Net Margin -3% +52.3%
ROE -1.53% +48.6%
ROIC -5.56% +48.5%
Debt/Equity 0.04 +19.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 86 (top 14%)
✓Strong 5Y sales CAGR of 28.2%
✓Share count reduced 3.5% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y28.2%

3Y16.14%

TTM-2.18%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-26.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-31.18%

ROCE

10Y Avg-5.34%

5Y Avg0.59%

3Y Avg-3.75%

Latest-4.72%

Peer Comparison

Medical Imaging Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRMDIRadimed Corporation	1.3B	102.57	68.38	11.71%	26.31%	21.54%	1.35%	0.00
BRKRBruker Corporation	7.52B	49.46	65.08	13.56%	-0.61%	-0.84%	1.81%	1.24
STESTERIS plc	26.33B	268.26	43.27	6.24%	12.07%	9.8%	2.95%	0.33
FONRFONAR Corporation	114.98M	18.64	15.15	1.43%	7.08%	4.62%	6.48%	0.24
HYPRHyperfine, Inc.	100.18M	1.22	-2.18	16.84%	-378.17%	-149.05%		0.01
PACBPacific Biosciences of California, Inc.	709.48M	2.35	-2.20	-23.19%	-325.8%	-13.95%		1.33
IRIXIRIDEX Corporation	23.21M	1.35	-2.50	-6.17%	-10.04%	-108.67%		2.21
MASS908 Devices Inc.	199.79M	5.52	-2.60	18.72%	-7.17%	-3.03%		0.06

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	57.88M	92.84M	127.95M	164.04M	193.01M	200.45M
Revenue Growth %	-	0.6%	0.38%	0.28%	0.18%	0.04%
Cost of Goods Sold+	29.21M	41.13M	48.81M	63.06M	83.59M	89.35M
COGS % of Revenue	0.5%	0.44%	0.38%	0.38%	0.43%	0.45%
Gross Profit+	28.67M	51.71M	79.14M	100.97M	109.43M	111.11M
Gross Margin %	0.5%	0.56%	0.62%	0.62%	0.57%	0.55%
Gross Profit Growth %	-	0.8%	0.53%	0.28%	0.08%	0.02%
Operating Expenses+	45.93M	38.05M	69.99M	102.78M	137.27M	131.63M
OpEx % of Revenue	0.79%	0.41%	0.55%	0.63%	0.71%	0.66%
Selling, General & Admin	16.98M	24.36M	45.55M	67.92M	93.12M	92.23M
SG&A % of Revenue	0.29%	0.26%	0.36%	0.41%	0.48%	0.46%
Research & Development	8.93M	13.69M	24.44M	34.86M	44.15M	39.4M
R&D % of Revenue	0.15%	0.15%	0.19%	0.21%	0.23%	0.2%
Other Operating Expenses	20.02M	0	0	0	0	0
Operating Income+	-17.26M	13.66M	9.16M	-1.8M	-27.84M	-20.52M
Operating Margin %	-0.3%	0.15%	0.07%	-0.01%	-0.14%	-0.1%
Operating Income Growth %	-	1.79%	-0.33%	-1.2%	-14.44%	0.26%
EBITDA+	-16.95M	14.26M	10.4M	3.85M	-18.61M	-10.03M
EBITDA Margin %	-0.29%	0.15%	0.08%	0.02%	-0.1%	-0.05%
EBITDA Growth %	-	1.84%	-0.27%	-0.63%	-5.83%	0.46%
D&A (Non-Cash Add-back)	309K	603K	1.24M	5.66M	9.23M	10.49M
EBIT	-16.29M	14.76M	7.68M	3.83M	-13.64M	-20.52M
Net Interest Income+	710K	-223K	-1.69M	2.05M	4.34M	10.36M
Interest Income	711K	110K	49K	4.62M	6.41M	10.36M
Interest Expense	1K	333K	1.74M	2.57M	2.07M	0
Other Income/Expense	962K	771K	-3.22M	3.06M	12.14M	14.82M
Pretax Income+	-16.29M	14.43M	5.94M	1.26M	-15.71M	-5.7M
Pretax Margin %	-0.28%	0.16%	0.05%	0.01%	-0.08%	-0.03%
Income Tax+	533K	-4.98M	2.91M	-1.22M	-3.56M	320K
Effective Tax Rate %	1.03%	1.35%	0.51%	2.04%	0.77%	1.06%
Net Income+	-16.83M	19.41M	3M	2.58M	-12.15M	-6.02M
Net Margin %	-0.29%	0.21%	0.02%	0.02%	-0.06%	-0.03%
Net Income Growth %	-	2.15%	-0.85%	-0.14%	-5.72%	0.5%
Net Income (Continuing)	-16.83M	19.41M	3.03M	2.48M	-12.15M	-6.02M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	343K	251K	0	0
EPS (Diluted)+	-0.13	0.02	0.03	0.02	-0.09	-0.05
EPS Growth %	-	1.19%	0.36%	-0.44%	-5.83%	0.49%
EPS (Basic)	-0.13	0.02	0.03	0.02	-0.09	-0.05
Diluted Shares Outstanding	132.99M	132.99M	133.75M	138.56M	135.28M	130.61M
Basic Shares Outstanding	132.99M	132.99M	133.75M	134.51M	135.28M	130.61M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	67.77M	208.62M	431.73M	454.02M	392.06M	396.45M
Cash & Short-Term Investments	30.12M	165.23M	364.62M	341.15M	262.41M	277.86M
Cash Only	30.12M	165.23M	364.62M	296.6M	167.3M	98.72M
Short-Term Investments	0	0	0	44.55M	95.11M	179.15M
Accounts Receivable	17.75M	18.1M	29.63M	50.88M	56.12M	60.59M
Days Sales Outstanding	111.9	71.18	84.53	113.2	106.13	110.32
Inventory	18.43M	23.02M	32.17M	48.15M	60.88M	43.89M
Days Inventory Outstanding	230.35	204.27	240.59	278.71	265.83	179.31
Other Current Assets	419K	1.33M	708K	6.7M	2.56M	1.97M
Total Non-Current Assets+	2.6M	11.36M	31.57M	65.46M	102.4M	103.05M
Property, Plant & Equipment	1.04M	2.14M	5.85M	27.57M	29.26M	28.13M
Fixed Asset Turnover	55.60x	43.38x	21.87x	5.95x	6.60x	7.13x
Goodwill	476K	476K	10.14M	10.14M	16.18M	16.66M
Intangible Assets	263K	274K	4.74M	4.33M	23.08M	20.13M
Long-Term Investments	0	0	0	0	1.6M	1.6M
Other Non-Current Assets	816K	1.09M	1.67M	2.96M	1.78M	3.16M
Total Assets+	70.36M	219.98M	463.31M	519.48M	494.46M	499.5M
Asset Turnover	0.82x	0.42x	0.28x	0.32x	0.39x	0.40x
Asset Growth %	-	2.13%	1.11%	0.12%	-0.05%	0.01%
Total Current Liabilities+	21.04M	26.54M	33.18M	49.04M	56.23M	67.66M
Accounts Payable	2.34M	2.94M	3.03M	4.8M	3.03M	5.53M
Days Payables Outstanding	29.27	26.13	22.69	27.81	13.24	22.59
Short-Term Debt	0	2.77M	0	580K	565K	4.66M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	10.51M	12.01M	12.04M	17.3M	21.2M	1.86M
Current Ratio	3.22x	7.86x	13.01x	9.26x	6.97x	5.86x
Quick Ratio	2.34x	6.99x	12.04x	8.28x	5.89x	5.21x
Cash Conversion Cycle	312.99	249.32	302.44	364.11	358.71	267.05
Total Non-Current Liabilities+	91.02M	209.47M	24.74M	44.89M	45.17M	36.1M
Long-Term Debt	0	0	0	2.27M	1.65M	1.05M
Capital Lease Obligations	0	0	0	12.31M	9.48M	7.55M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	89.24M	206.01M	14.95M	17.18M	18.91M	11.4M
Total Liabilities	112.06M	236.01M	57.92M	93.93M	101.39M	103.76M
Total Debt+	0	2.77M	0	18.09M	14.14M	17.02M
Net Debt	-30.12M	-162.46M	-364.62M	-278.51M	-153.16M	-81.7M
Debt / Equity	-	-	-	0.04x	0.04x	0.04x
Debt / EBITDA	-	0.19x	-	4.69x	-	-
Net Debt / EBITDA	-	-11.39x	-35.06x	-72.25x	-	-
Interest Coverage	-17256.00x	41.02x	5.26x	-0.70x	-13.45x	-
Total Equity+	-41.7M	-16.03M	405.38M	425.55M	393.06M	395.74M
Equity Growth %	-	0.62%	26.29%	0.05%	-0.08%	0.01%
Book Value per Share	-0.31	-0.12	3.03	3.07	2.91	3.03
Total Shareholders' Equity	-41.7M	-16.03M	405.04M	425.3M	393.06M	395.74M
Common Stock	21K	23K	126K	135K	131K	129K
Retained Earnings	-42.02M	-22.61M	-19.61M	-17.03M	-29.18M	-35.2M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-147K	65K	897K	-697K	-1.27M	16K
Minority Interest	0	0	343K	251K	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.75M	15.16M	4.63M	-12.23M	5.28M	25.38M
Operating CF Margin %	-0.24%	0.16%	0.04%	-0.07%	0.03%	0.13%
Operating CF Growth %	-	2.1%	-0.69%	-3.64%	1.43%	3.81%
Net Income	-16.83M	19.41M	3.03M	2.48M	-12.15M	-6.02M
Depreciation & Amortization	309K	603K	1.24M	5.66M	9.23M	10.49M
Stock-Based Compensation	269K	611K	6.59M	16.59M	22.05M	26.85M
Deferred Taxes	0	0	0	0	0	-2.89M
Other Non-Cash Items	1.34M	2.07M	2.42M	2.96M	-3.34M	-10.77M
Working Capital Changes	1.16M	-7.54M	-8.65M	-39.93M	-10.51M	7.71M
Change in Receivables	-12.61M	334K	-12.37M	-19.74M	-7.33M	-5.43M
Change in Inventory	-14.61M	-5.7M	-7.07M	-17.65M	4.29M	14.76M
Change in Payables	1.21M	-55K	-256K	1.86M	-1.78M	2.58M
Cash from Investing+	-973K	-1.55M	-20.99M	-55.91M	-93.89M	-82.97M
Capital Expenditures	-973K	-1.55M	-4.36M	-9.75M	-4.65M	-3.52M
CapEx % of Revenue	0.02%	0.02%	0.03%	0.06%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-120K	-179K	84K
Cash from Financing+	93K	122.61M	213.56M	5.51M	-41.81M	-15.82M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	93K	169K	642K	2.58M	2.9M	2.17M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-14.72M	13.61M	266K	-22.1M	454K	21.85M
FCF Margin %	-0.25%	0.15%	0%	-0.13%	0%	0.11%
FCF Growth %	-	1.92%	-0.98%	-84.08%	1.02%	47.14%
FCF per Share	-0.11	0.10	0.00	-0.16	0.00	0.17
FCF Conversion (FCF/Net Income)	0.82x	0.78x	1.54x	-4.75x	-0.43x	-4.22x
Interest Paid	0	0	0	0	0	0
Taxes Paid	144K	2.07M	2.86M	10.39M	5.3M	3.83M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	1.54%	0.62%	-2.97%	-1.53%
Return on Invested Capital (ROIC)	-	-	16.85%	-1.44%	-10.79%	-5.56%
Gross Margin	49.54%	55.7%	61.86%	61.56%	56.69%	55.43%
Net Margin	-29.07%	20.91%	2.35%	1.57%	-6.29%	-3%
Debt / Equity	-	-	-	0.04x	0.04x	0.04x
Interest Coverage	-17256.00x	41.02x	5.26x	-0.70x	-13.45x	-
FCF Conversion	0.82x	0.78x	1.54x	-4.75x	-0.43x	-4.22x
Revenue Growth	-	60.39%	37.82%	28.2%	17.67%	3.85%

Revenue by Segment

	2021	2022	2023	2024
Product	119.52M	148.6M	156.72M	153.26M
Product Growth	-	24.33%	5.46%	-2.20%
Service	8.43M	15.44M	36.49M	47.19M
Service Growth	-	83.09%	136.40%	29.32%

Revenue by Geography

	2021	2022	2023	2024
UNITED STATES	72.72M	94.59M	102.08M	92.61M
UNITED STATES Growth	-	30.07%	7.92%	-9.28%
EMEA	36.97M	43.96M	53.18M	62.34M
EMEA Growth	-	18.91%	20.97%	17.23%
Asia Pacific	16.08M	22.52M	31.6M	35.77M
Asia Pacific Growth	-	40.09%	40.29%	13.20%
Other	2.18M	2.96M	6.15M	9.73M
Other Growth	-	35.86%	107.69%	58.14%

Frequently Asked Questions

Growth & Financials

Cytek Biosciences, Inc. (CTKB) reported $196.8M in revenue for fiscal year 2024. This represents a 240% increase from $57.9M in 2019.

Cytek Biosciences, Inc. (CTKB) grew revenue by 3.9% over the past year. Growth has been modest.

Cytek Biosciences, Inc. (CTKB) reported a net loss of $12.8M for fiscal year 2024.

Dividend & Returns

Cytek Biosciences, Inc. (CTKB) has a return on equity (ROE) of -1.5%. Negative ROE indicates the company is unprofitable.

Cytek Biosciences, Inc. (CTKB) had negative free cash flow of $5.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cytek Biosciences, Inc. (CTKB) 10-Year Financial Performance & Capital Metrics

CTKB • • Industrial / General

HealthcareMedical DevicesDiagnostic & Imaging EquipmentMedical Imaging Systems

Revenue $200M +3.9%
EBITDA -$10M +46.1%
Net Income -$6M +50.4%
EPS (Diluted) -0.05 +48.7%
Gross Margin 55.43% -2.2%
EBITDA Margin -5.01% +48.1%
Operating Margin -10.24% +29.0%
Net Margin -3% +52.3%
ROE -1.53% +48.6%
ROIC -5.56% +48.5%
Debt/Equity 0.04 +19.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 86 (top 14%)
✓Strong 5Y sales CAGR of 28.2%
✓Share count reduced 3.5% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y28.2%

3Y16.14%

TTM-2.18%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-26.19%

EPS CAGR

10Y-

5Y-

3Y-

TTM-31.18%

ROCE

10Y Avg-5.34%

5Y Avg0.59%

3Y Avg-3.75%

Latest-4.72%

Peer Comparison

Medical Imaging Systems

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
IRMDIRadimed Corporation	1.3B	102.57	68.38	11.71%	26.31%	21.54%	1.35%	0.00
BRKRBruker Corporation	7.52B	49.46	65.08	13.56%	-0.61%	-0.84%	1.81%	1.24
STESTERIS plc	26.33B	268.26	43.27	6.24%	12.07%	9.8%	2.95%	0.33
FONRFONAR Corporation	114.98M	18.64	15.15	1.43%	7.08%	4.62%	6.48%	0.24
HYPRHyperfine, Inc.	100.18M	1.22	-2.18	16.84%	-378.17%	-149.05%		0.01
PACBPacific Biosciences of California, Inc.	709.48M	2.35	-2.20	-23.19%	-325.8%	-13.95%		1.33
IRIXIRIDEX Corporation	23.21M	1.35	-2.50	-6.17%	-10.04%	-108.67%		2.21
MASS908 Devices Inc.	199.79M	5.52	-2.60	18.72%	-7.17%	-3.03%		0.06

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	57.88M	92.84M	127.95M	164.04M	193.01M	200.45M
Revenue Growth %	-	0.6%	0.38%	0.28%	0.18%	0.04%
Cost of Goods Sold+	29.21M	41.13M	48.81M	63.06M	83.59M	89.35M
COGS % of Revenue	0.5%	0.44%	0.38%	0.38%	0.43%	0.45%
Gross Profit+	28.67M	51.71M	79.14M	100.97M	109.43M	111.11M
Gross Margin %	0.5%	0.56%	0.62%	0.62%	0.57%	0.55%
Gross Profit Growth %	-	0.8%	0.53%	0.28%	0.08%	0.02%
Operating Expenses+	45.93M	38.05M	69.99M	102.78M	137.27M	131.63M
OpEx % of Revenue	0.79%	0.41%	0.55%	0.63%	0.71%	0.66%
Selling, General & Admin	16.98M	24.36M	45.55M	67.92M	93.12M	92.23M
SG&A % of Revenue	0.29%	0.26%	0.36%	0.41%	0.48%	0.46%
Research & Development	8.93M	13.69M	24.44M	34.86M	44.15M	39.4M
R&D % of Revenue	0.15%	0.15%	0.19%	0.21%	0.23%	0.2%
Other Operating Expenses	20.02M	0	0	0	0	0
Operating Income+	-17.26M	13.66M	9.16M	-1.8M	-27.84M	-20.52M
Operating Margin %	-0.3%	0.15%	0.07%	-0.01%	-0.14%	-0.1%
Operating Income Growth %	-	1.79%	-0.33%	-1.2%	-14.44%	0.26%
EBITDA+	-16.95M	14.26M	10.4M	3.85M	-18.61M	-10.03M
EBITDA Margin %	-0.29%	0.15%	0.08%	0.02%	-0.1%	-0.05%
EBITDA Growth %	-	1.84%	-0.27%	-0.63%	-5.83%	0.46%
D&A (Non-Cash Add-back)	309K	603K	1.24M	5.66M	9.23M	10.49M
EBIT	-16.29M	14.76M	7.68M	3.83M	-13.64M	-20.52M
Net Interest Income+	710K	-223K	-1.69M	2.05M	4.34M	10.36M
Interest Income	711K	110K	49K	4.62M	6.41M	10.36M
Interest Expense	1K	333K	1.74M	2.57M	2.07M	0
Other Income/Expense	962K	771K	-3.22M	3.06M	12.14M	14.82M
Pretax Income+	-16.29M	14.43M	5.94M	1.26M	-15.71M	-5.7M
Pretax Margin %	-0.28%	0.16%	0.05%	0.01%	-0.08%	-0.03%
Income Tax+	533K	-4.98M	2.91M	-1.22M	-3.56M	320K
Effective Tax Rate %	1.03%	1.35%	0.51%	2.04%	0.77%	1.06%
Net Income+	-16.83M	19.41M	3M	2.58M	-12.15M	-6.02M
Net Margin %	-0.29%	0.21%	0.02%	0.02%	-0.06%	-0.03%
Net Income Growth %	-	2.15%	-0.85%	-0.14%	-5.72%	0.5%
Net Income (Continuing)	-16.83M	19.41M	3.03M	2.48M	-12.15M	-6.02M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	343K	251K	0	0
EPS (Diluted)+	-0.13	0.02	0.03	0.02	-0.09	-0.05
EPS Growth %	-	1.19%	0.36%	-0.44%	-5.83%	0.49%
EPS (Basic)	-0.13	0.02	0.03	0.02	-0.09	-0.05
Diluted Shares Outstanding	132.99M	132.99M	133.75M	138.56M	135.28M	130.61M
Basic Shares Outstanding	132.99M	132.99M	133.75M	134.51M	135.28M	130.61M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	67.77M	208.62M	431.73M	454.02M	392.06M	396.45M
Cash & Short-Term Investments	30.12M	165.23M	364.62M	341.15M	262.41M	277.86M
Cash Only	30.12M	165.23M	364.62M	296.6M	167.3M	98.72M
Short-Term Investments	0	0	0	44.55M	95.11M	179.15M
Accounts Receivable	17.75M	18.1M	29.63M	50.88M	56.12M	60.59M
Days Sales Outstanding	111.9	71.18	84.53	113.2	106.13	110.32
Inventory	18.43M	23.02M	32.17M	48.15M	60.88M	43.89M
Days Inventory Outstanding	230.35	204.27	240.59	278.71	265.83	179.31
Other Current Assets	419K	1.33M	708K	6.7M	2.56M	1.97M
Total Non-Current Assets+	2.6M	11.36M	31.57M	65.46M	102.4M	103.05M
Property, Plant & Equipment	1.04M	2.14M	5.85M	27.57M	29.26M	28.13M
Fixed Asset Turnover	55.60x	43.38x	21.87x	5.95x	6.60x	7.13x
Goodwill	476K	476K	10.14M	10.14M	16.18M	16.66M
Intangible Assets	263K	274K	4.74M	4.33M	23.08M	20.13M
Long-Term Investments	0	0	0	0	1.6M	1.6M
Other Non-Current Assets	816K	1.09M	1.67M	2.96M	1.78M	3.16M
Total Assets+	70.36M	219.98M	463.31M	519.48M	494.46M	499.5M
Asset Turnover	0.82x	0.42x	0.28x	0.32x	0.39x	0.40x
Asset Growth %	-	2.13%	1.11%	0.12%	-0.05%	0.01%
Total Current Liabilities+	21.04M	26.54M	33.18M	49.04M	56.23M	67.66M
Accounts Payable	2.34M	2.94M	3.03M	4.8M	3.03M	5.53M
Days Payables Outstanding	29.27	26.13	22.69	27.81	13.24	22.59
Short-Term Debt	0	2.77M	0	580K	565K	4.66M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	10.51M	12.01M	12.04M	17.3M	21.2M	1.86M
Current Ratio	3.22x	7.86x	13.01x	9.26x	6.97x	5.86x
Quick Ratio	2.34x	6.99x	12.04x	8.28x	5.89x	5.21x
Cash Conversion Cycle	312.99	249.32	302.44	364.11	358.71	267.05
Total Non-Current Liabilities+	91.02M	209.47M	24.74M	44.89M	45.17M	36.1M
Long-Term Debt	0	0	0	2.27M	1.65M	1.05M
Capital Lease Obligations	0	0	0	12.31M	9.48M	7.55M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	89.24M	206.01M	14.95M	17.18M	18.91M	11.4M
Total Liabilities	112.06M	236.01M	57.92M	93.93M	101.39M	103.76M
Total Debt+	0	2.77M	0	18.09M	14.14M	17.02M
Net Debt	-30.12M	-162.46M	-364.62M	-278.51M	-153.16M	-81.7M
Debt / Equity	-	-	-	0.04x	0.04x	0.04x
Debt / EBITDA	-	0.19x	-	4.69x	-	-
Net Debt / EBITDA	-	-11.39x	-35.06x	-72.25x	-	-
Interest Coverage	-17256.00x	41.02x	5.26x	-0.70x	-13.45x	-
Total Equity+	-41.7M	-16.03M	405.38M	425.55M	393.06M	395.74M
Equity Growth %	-	0.62%	26.29%	0.05%	-0.08%	0.01%
Book Value per Share	-0.31	-0.12	3.03	3.07	2.91	3.03
Total Shareholders' Equity	-41.7M	-16.03M	405.04M	425.3M	393.06M	395.74M
Common Stock	21K	23K	126K	135K	131K	129K
Retained Earnings	-42.02M	-22.61M	-19.61M	-17.03M	-29.18M	-35.2M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-147K	65K	897K	-697K	-1.27M	16K
Minority Interest	0	0	343K	251K	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-13.75M	15.16M	4.63M	-12.23M	5.28M	25.38M
Operating CF Margin %	-0.24%	0.16%	0.04%	-0.07%	0.03%	0.13%
Operating CF Growth %	-	2.1%	-0.69%	-3.64%	1.43%	3.81%
Net Income	-16.83M	19.41M	3.03M	2.48M	-12.15M	-6.02M
Depreciation & Amortization	309K	603K	1.24M	5.66M	9.23M	10.49M
Stock-Based Compensation	269K	611K	6.59M	16.59M	22.05M	26.85M
Deferred Taxes	0	0	0	0	0	-2.89M
Other Non-Cash Items	1.34M	2.07M	2.42M	2.96M	-3.34M	-10.77M
Working Capital Changes	1.16M	-7.54M	-8.65M	-39.93M	-10.51M	7.71M
Change in Receivables	-12.61M	334K	-12.37M	-19.74M	-7.33M	-5.43M
Change in Inventory	-14.61M	-5.7M	-7.07M	-17.65M	4.29M	14.76M
Change in Payables	1.21M	-55K	-256K	1.86M	-1.78M	2.58M
Cash from Investing+	-973K	-1.55M	-20.99M	-55.91M	-93.89M	-82.97M
Capital Expenditures	-973K	-1.55M	-4.36M	-9.75M	-4.65M	-3.52M
CapEx % of Revenue	0.02%	0.02%	0.03%	0.06%	0.02%	0.02%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-120K	-179K	84K
Cash from Financing+	93K	122.61M	213.56M	5.51M	-41.81M	-15.82M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	93K	169K	642K	2.58M	2.9M	2.17M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-14.72M	13.61M	266K	-22.1M	454K	21.85M
FCF Margin %	-0.25%	0.15%	0%	-0.13%	0%	0.11%
FCF Growth %	-	1.92%	-0.98%	-84.08%	1.02%	47.14%
FCF per Share	-0.11	0.10	0.00	-0.16	0.00	0.17
FCF Conversion (FCF/Net Income)	0.82x	0.78x	1.54x	-4.75x	-0.43x	-4.22x
Interest Paid	0	0	0	0	0	0
Taxes Paid	144K	2.07M	2.86M	10.39M	5.3M	3.83M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	1.54%	0.62%	-2.97%	-1.53%
Return on Invested Capital (ROIC)	-	-	16.85%	-1.44%	-10.79%	-5.56%
Gross Margin	49.54%	55.7%	61.86%	61.56%	56.69%	55.43%
Net Margin	-29.07%	20.91%	2.35%	1.57%	-6.29%	-3%
Debt / Equity	-	-	-	0.04x	0.04x	0.04x
Interest Coverage	-17256.00x	41.02x	5.26x	-0.70x	-13.45x	-
FCF Conversion	0.82x	0.78x	1.54x	-4.75x	-0.43x	-4.22x
Revenue Growth	-	60.39%	37.82%	28.2%	17.67%	3.85%

Revenue by Segment

	2021	2022	2023	2024
Product	119.52M	148.6M	156.72M	153.26M
Product Growth	-	24.33%	5.46%	-2.20%
Service	8.43M	15.44M	36.49M	47.19M
Service Growth	-	83.09%	136.40%	29.32%

Revenue by Geography

	2021	2022	2023	2024
UNITED STATES	72.72M	94.59M	102.08M	92.61M
UNITED STATES Growth	-	30.07%	7.92%	-9.28%
EMEA	36.97M	43.96M	53.18M	62.34M
EMEA Growth	-	18.91%	20.97%	17.23%
Asia Pacific	16.08M	22.52M	31.6M	35.77M
Asia Pacific Growth	-	40.09%	40.29%	13.20%
Other	2.18M	2.96M	6.15M	9.73M
Other Growth	-	35.86%	107.69%	58.14%

Frequently Asked Questions

Growth & Financials

Cytek Biosciences, Inc. (CTKB) reported $196.8M in revenue for fiscal year 2024. This represents a 240% increase from $57.9M in 2019.

Cytek Biosciences, Inc. (CTKB) grew revenue by 3.9% over the past year. Growth has been modest.

Cytek Biosciences, Inc. (CTKB) reported a net loss of $12.8M for fiscal year 2024.

Dividend & Returns

Cytek Biosciences, Inc. (CTKB) has a return on equity (ROE) of -1.5%. Negative ROE indicates the company is unprofitable.

Cytek Biosciences, Inc. (CTKB) had negative free cash flow of $5.9M in fiscal year 2024, likely due to heavy capital investments.